Learning from Smaller Scale Studies to Plan Effectively for Phase 3 Trials, Using Learnings From ALS

Time: 11:00 am
day: Day One


  • Utilizing biomarkers to characterize Treg response and impact on disease progression
  • Leveraging data to optimize dosage frequency and timing in treatment paradigm to have the most therapeutic impact
  • Presenting phase II trial data and discussing later stage trial development to optimize efficacy in large populations of ALS patients